FOXO Reaches Key Milestone, Shares Pop
FOXO Technologies Inc. (NYSE: FOXO) shares began Tuesday up more than double on word its behavioral health subsidiary, Myrtle Recovery Centers, Inc., has reached key patient care milestones. Since operations commenced at its Oneida, Tennessee location in August 2023, the facility has seen over 400 patients and has served patients for over 5,000 care days.Myrtle CEO Robert Merritt stated, “We are excited about reaching these important patient care milestones as they are indicative of the strong presence and reputation our facility has for delivering exemplary care for substance use disorder patients in East Tennessee. “We continue to increase our referral sources and believe we will have served 10,000 patient care days by year end 2025 since inception. We look forward to providing care for more residents in the area and are looking to expand our footprint to facilitate an increasing demand for our services.” FOXO CEO Seamus Lagan, further added, “we are pleased with our investment in Myrtle and how it has ramped up operations and made a significant impact in the rural communities Myrtle serves. We look forward to expanding Myrtle into additional locations and increasing the revenues this subsidiary contributes to FOXO.”FOXO shares began Tuesday up 82 cents, or 129.5%, to $1.46.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


